Ulcerative colitis

Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference

Retrieved on: 
Wednesday, April 3, 2024
Managed Care, Research, Radiology, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, Other Science, Conference, Medicine, Patient, UC, RNA, IBD, Inflammatory bowel disease, Ulcerative colitis, Therapy, Pharmaceutical industry

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.

Key Points: 
  • Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.
  • The data showcases the potential predictive capabilities of Geneoscopy’s noninvasive stool RNA biomarker technology in informing therapeutic response for patients with inflammatory bowel disease (IBD).
  • Our participation at IBD Innovate reaffirms our commitment to advancing precision immunology for patients with IBD."
  • The research examined stool-derived eukaryotic RNA (seRNA) to predict therapeutic response and disease activity in Crohn’s Disease (CD) and Ulcerative Colitis (UC).

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

Retrieved on: 
Wednesday, March 27, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCC, AbbVie, GPCR, Ulcerative colitis, Head, Alpha globulin, Survival, Data science, Data analysis, Drug discovery, Partnership, Hook effect, HNSCC, Boehringer Ingelheim, Inflammation, Patient, Research, RNA, Veloxis Pharmaceuticals, Cancer, Lung cancer, Bank statement, AACR, Investment, First, Therapy, ESMO, Collaboration, Hepatocellular carcinoma, RNA therapeutics, FDA, Artificial intelligence, Audit committee, Food, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.
  • Anne-Laure Autret-Cornet, Chief Financial Officer of OSE Immunotherapeutics, adds: “Our business-model is mostly based on recurrent and strategic partnerships with pharmaceutical companies.
  • A meeting of the Board of Directors of OSE Immunotherapeutics was held on March 27, 2024.
  • Following the Audit Committee opinion, the Board approved the annual and consolidated financial statements prepared under IFRS on 31 December 2023.

Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised Medicines

Retrieved on: 
Tuesday, March 26, 2024
Software, Biotechnology, Pharmaceutical, Health, Medical Devices, Health Technology, Technology, Clinical Trials, Disease, Ulcerative colitis, Risk, Partnership, Patient, NHS, Mortality, Pivot, Pharmacotherapy, Investment, Clinical trial, Annual report, Inflammatory bowel disease, Teva, Therapy, Hypertension, Medicine, Pharmaceutical industry

Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines.

Key Points: 
  • Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines.
  • Under the agreement, Closed Loop Medicine – a leading TechBio company – and pharmaceutical company, Teva UK, will investigate opportunities to use Closed Loop Medicine’s proprietary software as a medical device (SaMD) technology platform which aims to advance the development of personalised medicines, improve drug efficacy and outcomes in patients with specific chronic disorders by combining dose-optimised drug therapy with digital care.
  • Dr Paul Goldsmith, Chief Medical Officer and Innovation Officer, Co-Founder and President of Closed Loop Medicine, said: “As clinicians, we know that dosing of drugs is a huge problem.
  • Being able to predict personalised dose levels could be transformational.”
    This strategic partnership harnesses Closed Loop Medicine’s proprietary SaMD and combines it with Teva’s pharmaceutical products creating the opportunity for digital companions to be prescribed alongside traditional therapeutics, enabling real-world data integration and improved effectiveness of innovative and known medicines.

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
Monday, March 25, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AbbVie, Ulcerative colitis, Growth, I&I, Cell, ACG, Patient, ABBV, UC, Journal, Biomarker, NIMML, Acquisition, LANCL2, IPO, SLE, Personalized medicine, Volunteering, A.I, IBD, Medicine, Rheumatoid arthritis, Epithelium, DRS, Invention, Therapy, NLRX1, Work, Pharmaceutical industry

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers

Retrieved on: 
Monday, March 25, 2024
Professional Services, Health, Finance, Clinical Trials, Research, Science, Pharmaceutical, PDE10, Phases of clinical research, Ulcerative colitis, Brain, IL6, Disease, Tumor necrosis factor, Central nervous system, IL8, Benevolence, Patient, CNS, CGMP, UC, Camp, Șaeș, Trial of the century, BAI, Cytokine, Drug development, Safety, Inflammatory bowel disease, Euronext Amsterdam, Steroid, JAK, Pharmaceutical industry

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.
  • As a result, BenevolentAI’s scientists designed BEN-8744 to be not only a potent PDE10 inhibitor, but also a peripherally-restricted molecule, i.e.
  • The Phase Ia study results support this profile, showing no evidence of CNS-associated adverse events at any dose level.
  • It is anticipated that the full results from this study will be presented in a peer-reviewed forum at a later date.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

Global Irritable Bowel Disease (IBD) Market Analysis Report 2024: Increasing Prevalence of Crohn's Disease, and Ulcerative Colitis Driving the $21 Billion Market - Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
General Health, Pharmaceutical, Health, Corticosteroid, TNF, Injection (medicine), Growth, Prevalence, Porter's five forces analysis, Incidence, SWOT, Disease, Research, IBD, Market, Medicine, Crohn's disease, Route of administration, Ulcerative colitis, USD, Administration, JAK, Irritable bowel syndrome, Pharmaceutical industry

The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.

Key Points: 
  • The Global Irritable Bowel Disease market showcased growth at a CAGR of 2.60% during 2019-2022.
  • The increasing incidence and prevalence of Crohn's Disease, and Ulcerative Colitis are major drivers for the growth of the Market.
  • The report analyses the Irritable Bowel Disease Market by Drug Class (Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes)
    The report analyses the Irritable Bowel Disease Market By Route of Administration (Injectable, Oral).
  • The report analyses the Irritable Bowel Disease Market by Indication (Crohn's Disease, Ulcerative Colitis).

Takeda's 'In Their Shoes' Program Sheds Light on IBD Challenges in South Africa

Retrieved on: 
Friday, March 15, 2024
Disease, Caregiver, Abdominal pain, Empathy, Patient, Common, Gastrointestinal tract, Weight loss, Knowledge, Diarrhea, IBD, Shoe, Crohn's disease, Inflammatory bowel disease, Immune system, Ulcerative colitis, Fatigue, Pharmaceutical industry

JOHANNESBURG, March 12, 2024 /PRNewswire/ -- Takeda, the patient-focused biopharmaceutical firm, introduced its worldwide 'In Their Shoes' initiative to Johannesburg, South Africa. This effort, aimed at increasing awareness about the challenging symptoms of Inflammatory Bowel Disease (IBD), involved an immersive two-day simulation that provided profound insights into the impact of the disease on patients' daily lives.

Key Points: 
  • Takeda's 'In Their Shoes' program sheds light on the daily challenges faced by individuals with IBD in South Africa, promoting empathy and awareness
    JOHANNESBURG, March 12, 2024 /PRNewswire/ -- Takeda, the patient-focused biopharmaceutical firm, introduced its worldwide 'In Their Shoes' initiative to Johannesburg, South Africa.
  • [1] Whether Crohn's Disease or Ulcerative Colitis, IBD rates are increasing in South Africa.
  • Using a mobile app and an 'IBD kit,' participants engaged in common struggles, gaining insights into the disease's physical and emotional challenges.
  • Ursula Myles, Country Manager for South Africa, at Takeda, said, "At Takeda, our commitment to addressing life-limiting gastrointestinal diseases is unwavering.

EQS-News: Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
Janus, Psoriasis, Research, Webcast, German, MRI, General assembly, Biotechnology, Calcium, Expense, Regeneration, Capital punishment, SIRT6, Conference, Biomarker, AFL, Patent, PMS, Histology, Clinical trial, Investment, Ulcerative colitis, Magnetic resonance imaging, SPMS, Research and development, Multiple sclerosis, UC, Administration, Patient, Disease, RMS, Pharmaceutical industry

The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).

Key Points: 
  • The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).
  • The results demonstrated meaningful improvements over placebo in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .